07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

OncorMed, Cancer Research Campaign Technology, Duke University regulatory update

Cancer Research and Duke received U.K. Patent No. 52,307,477 covering the full length coding sequence of the BRCA2 gene, including pharmaceutical compositions, diagnostic methods and a method for producing the BRCA2 polypeptide. ONM holds an...
08:00 , Dec 19, 2005 |  BioCentury  |  Strategy

Cyclacel funding history

Cyclacel funding history Cyclacel funding history In the past decade, Cyclacel has raised over $100 million from an increasingly international group of investors; Raised in $M; ND = Not disclosed; Source: BioCentury Financial Center Date...
07:00 , Aug 4, 2003 |  BioCentury  |  Strategy

Bellwether thinking

The sentiment of European investors - both on the public equity side and the venture side - is remarkably negative when it comes to homegrown biotech, citing failed business models, thin pipelines and even thinner...
08:00 , Jan 29, 2001 |  BC Week In Review  |  Company News

Cancer Research Campaign Technology Ltd., Cancer Research Ventures Ltd. deal

Cancer Research Ventures will exclusively conduct technology transfer activities for business opportunities derived from research funded by Cancer Research Campaign Technology (CRCT). Research Ventures was spun out of the CRCT in 1998 to handle technology...
08:00 , Dec 7, 2000 |  BC Extra  |  Financial News

Vernalis banks 2.75 million

Vernalis (LSE:VER) divested its holding in Cancer Research Ventures (London, U.K.), the licensing and technology subsidiary of Cancer Research Campaign Technology, in exchange for 2.75 million ($4 million). The move comes after VER refined its...
07:00 , Sep 11, 2000 |  BC Week In Review  |  Company News

Viragen, University of Nottingham deal

VRA’s Viragen (Scotland) Ltd. subsidiary received an exclusive worldwide license to 791Tgp72, a tumor associated antigen, for use as a cancer vaccine . The technology was developed at the university and the U.K.’s Cancer Research...
07:00 , Aug 28, 2000 |  BC Week In Review  |  Company News

Viragen, Cancer Research Campaign Technology Ltd., University of Nottingham deal

Viragen (Scotland) Ltd., a subsidiary of VRA's Viragen (Europe) Ltd. subsidiary (Penicuick, U.K.), the university and CRCT will develop a cancer vaccine targeting complement inhibitor CD55 to treat breast, ovarian and colorectal cancers. Viragen Inc....
07:00 , Jul 31, 2000 |  BC Week In Review  |  Company News

Viragen, Cancer Research Campaign Technology Ltd., University of Nottingham deal

The parties will develop a cancer vaccine to treat breast, ovarian and colorectal cancers. The vaccine will target an antigen overexpressed in tumor cells discovered at a Cancer Research Campaign laboratory at the university. Viragen...
07:00 , May 1, 2000 |  BioCentury  |  Strategy

Vanguard, CeNeS seek mass

Consolidation as a means to build critical mass is still very much in the cards in the U.K. biotech sector. Vanguard Medica Group plc and CeNeS Pharmaceuticals plc - two companies that started life with...
08:00 , Dec 20, 1999 |  BC Week In Review  |  Company News

Onyvax, Cancer Research Campaign Technology, Institute of Cancer Research, Royal Marsden Hospital deal

The parties will identify genetic changes linked to the development and progression of prostate cancer to find drug targets. Onyvax will supply its cell immortalization technology to develop cell-lines from cancer tissues supplied by Royal...